50 related articles for article (PubMed ID: 25756405)
1. Fibroblast growth factor receptor 2 is associated with poor overall survival in clear cell carcinoma of the ovary and may be a novel therapeutic approach.
Itamochi H; Oumi N; Oishi T; Taniguchi F; Shoji T; Fujiwara H; Sugiyama T; Suzuki M; Kigawa J; Harada T
Int J Gynecol Cancer; 2015 May; 25(4):570-6. PubMed ID: 25756405
[TBL] [Abstract][Full Text] [Related]
2. Expression profiling in ovarian clear cell carcinoma: identification of hepatocyte nuclear factor-1 beta as a molecular marker and a possible molecular target for therapy of ovarian clear cell carcinoma.
Tsuchiya A; Sakamoto M; Yasuda J; Chuma M; Ohta T; Ohki M; Yasugi T; Taketani Y; Hirohashi S
Am J Pathol; 2003 Dec; 163(6):2503-12. PubMed ID: 14633622
[TBL] [Abstract][Full Text] [Related]
3. Sprouty2 correlates with favorable prognosis of gastric adenocarcinoma via suppressing FGFR2-induced ERK phosphorylation and cancer progression.
Xu Y; Yang X; Li Z; Li S; Guo S; Ismail S; Liu H; Huang Z; Zhang Z; Chen Y; Sun Q
Oncotarget; 2017 Jan; 8(3):4888-4900. PubMed ID: 28002800
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms of chemoresistance and poor prognosis in ovarian clear cell carcinoma.
Itamochi H; Kigawa J; Terakawa N
Cancer Sci; 2008 Apr; 99(4):653-8. PubMed ID: 18377417
[TBL] [Abstract][Full Text] [Related]
5. Epigenetic determinants of ovarian clear cell carcinoma biology.
Yamaguchi K; Huang Z; Matsumura N; Mandai M; Okamoto T; Baba T; Konishi I; Berchuck A; Murphy SK
Int J Cancer; 2014 Aug; 135(3):585-97. PubMed ID: 24382740
[TBL] [Abstract][Full Text] [Related]
6. Do Fibroblast Growth Factor Receptor (FGFR) 2 and 3 Proteins Play a Role in Prognosis of Invasive Urothelial Bladder Carcinoma?
Mahmoud SF; Holah NS; Alhanafy AM; Serag El-Edien MM
Iran J Pathol; 2024; 19(1):81-88. PubMed ID: 38864084
[TBL] [Abstract][Full Text] [Related]
7. Targeting of human fibroblast growth factor receptor 2 by a novel specific nanobody.
Irani M; Habibi-Anbouhi M; Behdani M; Kazemi-Lomedasht F
Prep Biochem Biotechnol; 2024; 54(3):307-316. PubMed ID: 37452673
[TBL] [Abstract][Full Text] [Related]
8. Stage 4 pancreatic adenocarcinoma harbouring an
Poon D; Tan MH; Khor D
BMJ Case Rep; 2021 Sep; 14(9):. PubMed ID: 34511423
[TBL] [Abstract][Full Text] [Related]
9. First Selective Small Molecule Inhibitor of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 Signaling Pathway.
Hagel M; Miduturu C; Sheets M; Rubin N; Weng W; Stransky N; Bifulco N; Kim JL; Hodous B; Brooijmans N; Shutes A; Winter C; Lengauer C; Kohl NE; Guzi T
Cancer Discov; 2015 Apr; 5(4):424-37. PubMed ID: 25776529
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapeutic approaches to ovarian cancer treatment.
Chester C; Dorigo O; Berek JS; Kohrt H
J Immunother Cancer; 2015; 3():7. PubMed ID: 25806106
[TBL] [Abstract][Full Text] [Related]
11. Crosstalk between PI3K and Ras pathways via protein phosphatase 2A in human ovarian clear cell carcinoma.
Takai M; Nakagawa T; Tanabe A; Terai Y; Ohmichi M; Asahi M
Cancer Biol Ther; 2015; 16(2):325-35. PubMed ID: 25756515
[TBL] [Abstract][Full Text] [Related]
12. The C342R mutation in FGFR2 causes Crouzon syndrome with elbow deformity.
Ke R; Yang X; Tianyi C; Ge M; Lei J; Mu X
J Craniofac Surg; 2015 Mar; 26(2):584-6. PubMed ID: 25759925
[TBL] [Abstract][Full Text] [Related]
13. Paralog-Specific Kinase Inhibition of FGFR4: Adding to the Arsenal of Anti-FGFR Agents.
Packer LM; Pollock PM
Cancer Discov; 2015 Apr; 5(4):355-7. PubMed ID: 25847957
[TBL] [Abstract][Full Text] [Related]
14. FGFR2 Assessment in Gastric Cancer Using Quantitative Real-Time Polymerase Chain Reaction, Fluorescent In Situ Hybridization, and Immunohistochemistry.
Park YS; Na YS; Ryu MH; Lee CW; Park HJ; Lee JK; Park SR; Ryoo BY; Kang YK
Am J Clin Pathol; 2015 Jun; 143(6):865-72. PubMed ID: 25972329
[TBL] [Abstract][Full Text] [Related]
15. Antitumor effects of interleukin-6 (IL-6)/interleukin-6 receptor (IL-6R) signaling pathway inhibition in clear cell carcinoma of the ovary.
Yanaihara N; Hirata Y; Yamaguchi N; Noguchi Y; Saito M; Nagata C; Takakura S; Yamada K; Okamoto A
Mol Carcinog; 2016 May; 55(5):832-41. PubMed ID: 25856562
[TBL] [Abstract][Full Text] [Related]
16. Fibroblast growth factor receptor isotype expression and its association with overall survival in patients with hepatocellular carcinoma.
Lee HJ; Kang HJ; Kim KM; Yu ES; Kim KH; Kim SM; Kim TW; Shim JH; Lim YS; Lee HC; Chung YH; Lee YS
Clin Mol Hepatol; 2015 Mar; 21(1):60-70. PubMed ID: 25834803
[TBL] [Abstract][Full Text] [Related]
17. FGFR2 regulates Mre11 expression and double-strand break repair via the MEK-ERK-POU1F1 pathway in breast tumorigenesis.
Huang YL; Chou WC; Hsiung CN; Hu LY; Chu HW; Shen CY
Hum Mol Genet; 2015 Jun; 24(12):3506-17. PubMed ID: 25788520
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
